Cancer Biomarkers

Cancer biomarkers are molecules, genes, or proteins found in tissues, blood, or other body fluids that indicate the presence or progression of cancer. These biomarkers can be diagnostic, helping to detect cancer early, or prognostic, predicting the course of the disease. Predictive biomarkers guide treatment decisions by indicating how a patient might respond to specific therapies, such as targeted treatments or immunotherapies. Common biomarkers include HER2 in breast cancer, PSA in prostate cancer, and CA-125 for ovarian cancer. Advances in biomarker research are improving personalized medicine, allowing treatments to be tailored to an individual’s unique cancer profile. Additionally, cancer biomarkers aid in monitoring treatment efficacy and detecting recurrence, making them crucial tools in cancer management and therapy development.

    Related Conference of Cancer Biomarkers

    November 25-26, 2024

    7th International Conference on Anti-Cancer Drugs & Therapies

    Vancouver, Canada
    November 28-29, 2024

    14th World Congress on Breast Cancer

    Paris, France
    December 10-11, 2024

    8th Global Meeting on Oncology and Radiology

    Dubai, UAE
    December 11-12, 2024

    34th Experts Meet On Cancer Research & Therapy

    Paris, France
    December 12-13, 2024

    44th Euro Congress on Cancer Science & Therapy

    Rome, Italy
    March 10-11, 2025

    3rd World Congress on Oral Cancer

    Paris, France
    March 24-25, 2025

    10th World Conference on Breast and Cervical Cancer

    Paris, France
    March 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    London, UK
    June 16-17, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands

    Cancer Biomarkers Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in